Top 5 Health Care Stocks That May Fall Off A Cliff
Portfolio Pulse from Lisa Levin
The article lists five health care stocks that are considered overbought, indicating they may be overvalued and could experience a price drop. The stocks are Aspira Women's Health Inc. (AWH), Novo Integrated Sciences, Inc. (NVOS), IDEAYA Biosciences, Inc. (IDYA), NeuroPace, Inc. (NPCE), and AN2 Therapeutics, Inc. (ANTX). The Relative Strength Index (RSI) of these stocks is above 70, which is typically considered overbought.

September 06, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AN2 Therapeutics' stock is considered overbought with an RSI of 73.15. The stock fell 2.3% to settle at $14.90 on Tuesday.
The high RSI indicates that the stock is overbought and could experience a price drop. The recent 2.3% fall in price supports this prediction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Aspira Women's Health's stock is considered overbought with an RSI of 72.25. The stock fell 18.3% to close at $4.90 on Tuesday.
The high RSI indicates that the stock is overbought and could experience a price drop. The recent 18.3% fall in price supports this prediction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
IDEAYA Biosciences' stock is considered overbought with an RSI of 72.99. The stock fell 3.2% to close at $28.81 on Tuesday.
The high RSI indicates that the stock is overbought and could experience a price drop. The recent 3.2% fall in price supports this prediction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
NeuroPace's stock is considered overbought with an RSI of 78.26. The stock fell 2.7% to close at $8.69 on Tuesday.
The high RSI indicates that the stock is overbought and could experience a price drop. The recent 2.7% fall in price supports this prediction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Novo Integrated Sciences' stock is considered overbought with an RSI of 76.26. The stock jumped 35.8% to close at $0.2920 on Tuesday.
The high RSI indicates that the stock is overbought and could experience a price drop. The recent 35.8% jump in price could be a sign of overvaluation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100